No Time to Die: How Kidney Cancer Evades Cell Death

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Renal cell carcinoma (kidney cancer) pathogenesis understanding led to targeted therapies improving survival.
• Despite advances, prognosis for many kidney cancer patients remains poor.
• Programmed cell death pathways, including p53, are often impaired in kidney cancer.

Purpose of the Study:

• To review programmed cell death modalities in renal cell carcinoma pathogenesis.
• To summarize in vitro and in vivo evidence of cell death's role in controlling kidney cancer growth.
• To highlight the therapeutic potential of targeting cell death pathways in kidney cancer.

Main Methods:

• Literature review of studies on programmed cell death in renal cell carcinoma.
• Analysis of in vitro and in vivo experimental evidence.
• Examination of targeted pharmacological interventions.

Main Results:

• Kidney cancer exhibits impaired apoptosis, ferroptosis, pyroptosis, and necroptosis, facilitating tumor growth.
• Targeted pharmacological interventions demonstrated the ability to reactivate these cell death mechanisms.
• Evidence suggests these pathways can be therapeutically exploited to control kidney cancer.

Conclusions:

• Reactivating programmed cell death pathways presents a promising therapeutic strategy for renal cell carcinoma.
• Further research into targeting apoptosis, ferroptosis, pyroptosis, and necroptosis is warranted for kidney cancer treatment.
• Understanding cell death's role is crucial for developing novel kidney cancer therapies.